Nabriva Therapeutics Ag Stock Revenue
Nabriva Therapeutics AG fundamentals help investors to digest information that contributes to Nabriva Therapeutics' financial success or failures. It also enables traders to predict the movement of Nabriva Stock. The fundamental analysis module provides a way to measure Nabriva Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nabriva Therapeutics stock.
Nabriva |
Nabriva Therapeutics AG Company Revenue Analysis
Nabriva Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Nabriva Therapeutics Revenue | 35.67 M |
Most of Nabriva Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Nabriva Therapeutics AG reported 35.67 M of revenue. This is 99.53% lower than that of the Pharmaceuticals sector and 95.2% lower than that of the Health Care industry. The revenue for all United States stocks is 99.62% higher than that of the company.
Nabriva Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.Nabriva Therapeutics is currently under evaluation in revenue category among its peers.
Nabriva Fundamentals
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| Gross Profit | (10.23 M) | |||
| EBITDA | (54.7 M) | |||
| Net Income | (57.19 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.81 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Short Ratio | 8.58 X | |||
| Earnings Per Share | (19.67) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 39 | |||
| Beta | 1.56 | |||
| Market Capitalization | 4.55 M | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Working Capital | 3.5 M | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
| Z Score | -32.68 | |||
| Net Asset | 31.77 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |